Top Small Cap Companies To Own For 2015

Top Small Cap Companies To Own For 2015: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Keith Speights]

  2. Achillion Pharmaceuticals (NASDAQ: ACHN  )
  Achillion recently experienced a delay in the game that it had hoped to play. The FDA placed a clinical hold on hepatitis C drug sovaprevir after patients in a phase 1 drug-drug interaction study with the drug combined with ritonavir-boosted atazanavir were found to have elevated liver enzyme levels. Shares dropped 25% in one day as a result.

• [By Roberto Pedone]

  An under-$10 biotechnology player that's starting to trend within range of triggering a big breakout trade is Achillion Pharmaceuticals (ACHN), discovers, develops and commercializes anti-infective drug therapies in the U.S. and internationally. This stock has been destroyed by the sellers so far in 2013, with shares down big by 66%! .

  If you take a look at the chart for Achillion Pharmaceuticals, you'll notice that this stock has been trending sideways for the last month and change, with shares moving between $2.26 on the downside and $2.98 on the upside. This sideways trading pattern is occurring after shares of ACHN gapped down sharply in late September from $7.50 to under $3 with heavy downside volume. Shares of ACHN are now starting to trend higher and move within range of triggering a big breakout trade above the upper-end of its sideways trading chart pattern.

  Traders should now look for long-biased trades in ACHN if it manages to break out above some near-term overhead resistance levels at $2.85 to $2.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.76 million shares. If that breakout triggers soon, then ACHN will set up to re-test or possibly take out its gap down day high from September at $3.62 a share. Any high-volume move above that level will then give ACHN a chance to re-fill some of its previous gap down zone that started at $7.50 a share.

  Traders can look to buy ACHN off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.44 to $2.26 a share. One can also buy ACHN off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Sean Williams]

  With a gain year-to-date of 328% -- that's three hundred and twenty eight percent -- clinical-stage HCV-focused Achillion Pharmaceuticals (NASDAQ: ACHN  ) absolutely crushed Gilead in total return this year. Amazingly, it did so without having a single product on pharmacy shelves.

• [By John Udovich]

  Small cap hepatitis stockAchillion Pharmaceuticals, Inc (NASDAQ: ACHN) saw shares jump on Monday only to then have a minor implosion on! Tuesday ! meaning its worth taking a look at that hiccup andthe history of hiccups orsuccesses from other small cap hepatitis stocks like Idenix Pharmaceuticals Inc (NASDAQ: IDIX),Arrowhead Research Corp (NASDAQ: ARWR) and Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). It should be mentioned that Hepatitis A, B and C are viral infections that together affect an estimated 5% to 6% of Americans and while globally, 2 billion people (1 out of 3 people) have been infected with hepatitis B with 400 million people chronically infected plus 130150 million people have chronic hepatitis C - meaning there is plenty of room for large and small cap players alike in the space.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-small-cap-companies-to-own-for-2015.html